Analyst Sentiment Shifts on Medtronic Amid Strategic Spin-Off

Wall Street revises Medtronic price targets lower due to sector valuation pressure and the upcoming MiniMed spin-off, though the average target remains above current price.

Medtronic shares are facing a reassessment from Wall Street, with several prominent analysts revising their price targets downward. The medical device giant's upcoming spin-off of its diabetes unit, MiniMed, combined with a sector-wide valuation recalibration, is introducing near-term caution among investors. Market participants are now closely monitoring the company's operational performance in the coming quarters for signs of stability.

A Spectrum of Revised Forecasts

A notable adjustment came from Citigroup, which lowered its price target to $110 from $117 and simultaneously removed the stock from its favored list. Analyst Joanne Wuensch cited a broad-based compression of valuation multiples across the medical technology sector as the primary reason. Evercore ISI also made a slight downward revision, setting a new target of $108, though it joined Citigroup in maintaining a "Buy" rating.

A more conservative stance is held by Stifel, which sees fair value at just $95 per share. Its analysis centers on the anticipated financial impact of the MiniMed separation. Sector specialists predict the spin-off process will create a modest dilution in earnings per share until the transaction is fully completed.

Underlying Strengths and Technical Position

Despite these adjustments, the consensus view among the approximately 30 analysts covering the stock remains positive, with an average price target near $110—still a premium to the current trading level. Optimistic firms like Argus Research have held their target steady at $115, emphasizing Medtronic's entrenched market leadership. The company continues to play a pivotal role in specialized vascular devices, such as drug-coated balloons, supported by its extensive product portfolio.

A summary of recent analyst actions:

• Argus: $115 (Buy)
• Citigroup: $110 (Buy)
• Evercore ISI: $108 (Buy)
• Stifel: $95 (Hold)

From a technical perspective, the stock appears oversold, with a Relative Strength Index (RSI) reading of 22.0. This follows a decline of approximately 8.5% since the start of the year. The critical focus for the next six months will be the execution of the structural realignment via the MiniMed spin-off and whether the company's core business can operationally offset the expected dilutive effects.